Tamarly Intelligence
Company · Private

Rgenta Therapeutics, Inc.

Share this pageLinkedInXEmail
Key figures
SEC number
1801266

Source: SEC EDGAR filings and company facts; checked 4 Nov 2026

About

Rgenta Therapeutics is a clinical-stage biotechnology company developing oral small molecule medicines that target RNA, with a focus on cancer and neurological disorders.

Rounds and raises
3 Nov 2026
Form D: $42M sold of $130M offered, Other Technology SEC

Source: SEC EDGAR Form D and the linked articles. All raises this week

Questions and answers

What does Rgenta Therapeutics, Inc. do?
Rgenta Therapeutics is a clinical-stage biotechnology company developing oral small molecule medicines that target RNA, with a focus on cancer and neurological disorders.
Free, with no account

The rest of this page is free to read: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.

Explore for freeSign in

Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.